欧州バイオテクノロジー産業クラスター・中小企業　対日ミッション　参加企業一覧

2019 EU Biotechnology Cluster / SME Mission Participants List

EU-Japan Centre for Industrial Cooperation / 日欧産業協力センター

	Country	Company/Organisation Name 企業・団体名	URL	Company descriptions / 企業説明
1	Denmark (DK)	Biomodics Aps	http://www.biomodics.com/	Biomodics do specialty polymers, drug delivery, nano particles and regenerative medicine.
2	Hungary (HU)	CRU Hungary Ltd.	www.cruint.com www.cru-global.com	Clinical research and Basic research from pre-clinical up to Phase IV real world studies
3	France (FR)	Genopole	https://www.genopole.fr/?lang=en#	French leading Biocluster located in the Paris region with over 90 innovating biotech companies.
4	Spain (ES)	Histocell, S.L.	www.histocell.com	Cell therapy drugs and medical devices for regenerative medicine.
5	France (FR)	Inoviem Scientific	www.inoviem.com	Clinical ON/OFF target ID and MoA elucidation, patient stratification, predictive biomarker ID.
6	Czech Republic (CZ)	IOCB Tech	https://www.iocbtech.cz/	IOCB Prague – a leading scientific institution in the Czech Republic and has tradition and expertise in drug development together with pharma industry. IOVB Tech – translation of IOCB's fundamental research results
7	Finland (FI)	Labmaster Oy	http://labmaster.fi	Design, development and manufacturing Medical devices and IVD tests.
8	France (FR)	Novaptech	https://novaptech.com	Aptamer-based biosensor design; custom Aptamer selection for therapeutics, diagnostics & analytics.
9	France (FR)	OpLysis SAS	http://www.op2lysis.com	Op2Lysis is dedicated to develop the best-in-class medical treatment for hemorrhagic stroke patients.
10	Sweden (SE)	PROSILICO	http://prosilico.com/	Computational predictions of ADME/PK of drug candidates and other chemicals
11	Poland (PL)	Real Reserch Sp z o.o.	https://realresearch.life/	3D cell culture, drug research, hydrogel for 3D cell cultures, cancer research, R&D.
12	Germany (DE)	Taros Chemicals GmbH & Co. KG	https://www.taros.de	Drug Discovery, Computational and Medicinal Chemistry.

参加企業・団体は予告なく変更となる場合がございます。　2019/9/24 現在

participating companies/ organisations are subject to change without further notice.　As of 2019/9/24

Inquiries : EU-Japan Centre for Industrial Cooperation (Fabrizio Mura, Daniel Gralki, Masae Ozawa)
Tel: 03-6408-0281 | e-mail: info-jp@een-japan.eu | Website: http://www.een-japan.eu

EU-Japan Centre for Industrial Cooperation 日欧産業協力センター

enterprise europe network Business Support on Your Doorstep

European Commission

Specialty polymers, regenerative medicine, drug delivery, nano particles
特殊ポリマー、再生医療、薬物送達、ナノ粒子

会社名 Biomodics Aps
国名 Denmark (DK)
ウェブサイト www.biomodics.com

設立 2010/1/1
社員数 < 10 employees
社員数 グループ < 49 employees
売上 (EUR) < 1 million
売上 (EUR) グループ < 1 million

会社概要

Biomodics innovate biocompatibility and local drug delivery via new specialty polymers and nanoparticles.
Biomodics is leveraging its unique expertise in polymer science to develop novel treatments. Our patented technology comprises scaffolds, regenerative medicine, and polymers for drug delivery. Biomodics also offer contract R&D.

Biomodicsは、新しい特殊ポリマーとナノ粒子により、生体適合性と局所への薬物送達技術を革新します。
Biomodicsは高分子科学における独自の専門技術を活かし、新規治療法を開発しています。私たちは、足場(スキャホールド)材料、再生医療、薬物送達用ポリマーの技術に関する特許を取得しています。Biomodicsは、委託研究開発もお請けいたします。

製品・技術

The company develops innovative solutions for silicone medical devices. Silicone is the material of choice for many applications like urinary catheters, vascular grafts and contact lenses due to its desirable properties such as chemical inertness and high flexibility. However, a common issue with silicone is the formation of bacterial biofilm inside and outside the tube. Biomodics' patented IPN technology makes the development of new silicone medical tubing devices resistant to biofilm formation possible due to an impregnation creating a storage depot for drugs allowing for sustained drug delivery. Furthermore, biocompatibility aid new products in performing better than existing products. Finally, sustained drug delivery is a huge advantage for pharmaceutical companies chasing new formulations and local drug delivery to obtain better treatments of diseases while reducing unwanted side-effects. This strategy will also allow patent extensions on new and existing drugs in combination with Biomodics drug delivery platform. Learn more at: www.biomodics.com

製品・技術の特徴

Biomodics products are innovative because they are based on effective post-treatment of existing polymer products with a new hydrogel nano-network. This enables the new products to gain permanent biocompatibility and optionally release drugs in a sustained way compared to coatings which are often weak and fragile. Applications range from drug delivery devices to contact lenses to medical devices intended for prolonged use and critical applications such as catheters for critically ill patients. The benefit is better product performance, improved safety and in case of new formulations the added benefit of patent extension of new and existing drugs are obvious. Therefore, contact to pharma players are of high relevance. They can benefit from designing sustained and local drug delivery. Potentially this can also lead to major socioeconomic benefits in relation to cancer and infectious diseases.

Clinical research and Basic research from pre-clinical up to Phase IV real world studies
非臨床試験から市販後の第IV相試験まで、臨床および基礎研究を実施

会社名 CRU Hungary Ltd.
国名 Hungary (HU)
ウェブサイト www.cruint.com and www.cru-global.com

設立 2007年1月
社員数 10 - 49 employees **社員数 グループ** 50 - 249 employees
売上 (EUR) 1 to 10 **売上 (EUR) グループ** 1 to 10

会社概要

Clinical Research Units Hungary (CRU) is a hospital-based Clinical Research Centre Network for conducting outpatient and inpatient clinical trials involving Pharmaceutical, Biological and Medical Devices, founded in 2007. CRU is currently the biggest Phase I unit and one of the biggest clinical research centers for later phase studies in Hungary.

2007年に設立されたClinical Research Units (CRU) Hungaryは、病院を拠点とした臨床研究センターのネットワークであり、外来患者ならびに入院患者の協力のもと、医薬品、生物製剤、医療機器の治験を実施しています。
CRUは現在、ハンガリー最大の第I相ユニットであるとともに、第II相以降の治験も実施可能な大規模臨床研究センターの一つです。

製品・技術

- Biomarker research
- Preclinical studies
- Phase I studies in Europe and Asia
- Phase II, III and IV studies in Europe and Asia
- Clinical research consulting, protocol writing, CRO activities

製品・技術の特徴

We provide high quality early clinical development services (confirmed by many FDA and other regulatory inspections and over 30 Pharma audits) for startup companies, small biotechs providing the Preclinical, Phase I and Phase II studies (the most critical part of drug development process due to the high failure rate) as a package for a much smaller budget than the Pharma and Biotech companies spend on it (and usually with much shorter timelines), as we can do all these activities within our own facilities with our permanent staff in 2 continent. We offer these services also for Venture Capital companies who invest in startups and SMEs in the field of drug development, saving a lot of money and also giving opportunities for companies with limited budget and resources.

French leading Biocluster located in the Paris region with over 90 innovating biotech companies
パリ地域に位置する主要バイオクラスター。90社以上の革新的なバイオテクノロジー企業が集結

会社名 **Genopole**
国名 France (FR)
ウェブサイト https://www.genopole.fr/?lang=en#

設立 1998年1月
社員数 **社員数 グループ**
売上 (EUR) **売上 (EUR) グループ**

会社概要 Genopole's overall mission is to support R&D in genomics and genetics and the grow of biotechnology SMEs that pursue health, environmental and agri-food applications. Genopole is a not-for-profit organisation, which is acting as general manager, advocate, promoter, catalyst, facilitator, coordinator, and sometimes financial sponsor of the biocluster member's developments.

Genopoleの総合的ミッションは、ゲノム学および遺伝学分野における研究開発へのサポートおよび健康、環境、農業食品への応用を目指すバイオテクノロジー関連中小企業の成長を支援することです。Genopoleはゼネラルマネージャー、支援者、プロモーター、カタリスト、ファシリテーター、コーディネーター、そして時にはバイオクラスターメンバー育成の資金後援者として活動する非営利団体です。

製品・技術 Genopole's principal objectives are to:
Support and coordinate R&D efforts and innovation initiatives in genomics and post-genomics sciences and technology;
Promote the growth of French biotechnology markets through direct incubation and business support services to start-ups and early-stage companies;
Provide cutting-edge shared-access technological platforms to the laboratories and companies that request them to conduct their researches;
Provide entrepreneurship training programmes, as well as reinforce targeted teaching programmes in close collaboration with the Université d'Evry Paris-Saclay and the Université Paris-Saclay;
Facilitate communications between the biocluster's stakeholders by organizing scientific and networking events on site as well as by reaching out to the media and the general public at large to generate a better understanding of the positive impact of genomics;

製品・技術の特徴
Why should partners choose you for cooperation?:
Founded in 1998, Genopole can provide a 20-years of knowledge and expertise in Life sciences and more particularly in genomics biotherapies, synthetic biology and entrepreneurship.
An innovation and business ecosystem with more than 2,300 staff members which are employed by 87 companies, 17 public research labs, and 28 cutting-edge shared-access technology platforms and facilities for R&D.
A mature and fertile biotech ecosystem with innovative companies and over 190 start-ups which have been accredited by Genopole over the last two decades, and have been assisted though customised specialised R&D and business support services. During that period, over €649 million have been raised by Genopole's portfolio companies, and seven companies have been already listed on public markets.

HC016 and Bonecure clinical stage adipose-derived stem cells (ASC) therapies technology platform
HC016細胞および脂肪由来幹細胞(ASC)を用いた臨床段階にある治療法、Bonecureなどのテクノロジープラットフォーム

会社名 Histocell, S.L.
国名 Spain (ES)
ウェブサイト www.histocell.com

設立 2004年1月
社員数 10 – 49 employees **社員数 グループ** < 49 employees
売上 (EUR) < 1 million **売上 (EUR) グループ**

会社概要

Clinical-stage biopharmaceutical company developing Cell Therapy Products for the treatment of multiple diseases, including Acute Spinal Cord Injury (Phase II) and Acute Respiratory Distress Syndrome (ARDS). Histocell has also developed regenerative medicine products on the market as REOXCARE, new medical device for wound healing. GMP production of cell therapy products and medical devices for 3rd parties.

Histocellは、臨床段階にあるバイオ医薬品会社であり、急性脊髄損傷(第II相)や急性呼吸窮迫症候群(ARDS)などの様々な疾患を治療する細胞療法製品を開発しています。Histocellはまた、創傷治癒の新しい医療機器である、再生医療製品のREOXCAREを開発、販売しています。GMP準拠施設で細胞療法製品や医療機器の委託製造も行っています。

製品・技術

Histocell has several cell therapy clinical studies ongoing based on its patented proprietary cell therapy technology platform HC016, an allogenic preconditioned Adult Mesenquimal Stem Cells platform to develop therapeutics for pathologies where oxidative damage takes place. Currently, three main therapeutic areas are being studied: CNS protection & repair, lung therapy and bone regeneration.
In the area of medical devices, the main product of Histocell is REOXCARE, a wound dressing with antioxidant properties for early phases in all kinds of wounds. REOXCARE is being marketed in some countries of Latin America, Europe and the Middle East, and seeks to agree more international commercialisation agreements in the coming years, for example, Japan.
Histocell manufacturing capacity embraces GMP production of cell therapy products for third parties, since the company is currently manufacturing clinical grade cells for several trials taking place in top-ranked hospitals in Spain.

製品・技術の特徴

HC016 are propietary mesenchimal Stem Cells (MSC) that have been preconditioned to be more resistant to oxidative stress and inflammatory situations than native mesenchimal stem cells. HC016 can be considered as new generation of Mesenchimal stem cells, although from a regulatory point of view they are considered as MSC as genetically, no change has been performed.
HC016 have a strong IP behind, with granted patent in main territories, including Japan.

Clinical ON/OFF target ID and MoA elucidation, patient stratification, predictive biomarker ID
臨床におけるオン/オフターゲットの特定、作用機序の解明、患者の層別化、予測バイオマーカーの選定

会社名 Inoviem Scientific
国名 France (FR)
ウェブサイト www.inoviem.com

設立 2011年1月
社員数 10 - 49 employees **社員数 グループ**
売上 (EUR) 1 to 10 **売上 (EUR) グループ**

会社概要 Biotech company with innovative label-free technologies for the identification native functional interactomes of pharmacological agents, to identify their targets, ON and OFF, to elucidate their mechanism of action and to identify predictive biomarkers of the compound efficiency, directly from human samples.

薬剤のネイティブな機能的インタラクトームを同定する革新的なラベルフリー技術を備えたバイオテクノロジー企業です。この技術により、薬剤のオン/オフターゲットの識別、作用メカニズムの解明、化合物の有効性予測バイオマーカーの同定を、ヒトサンプルから直接行うことができます。

製品・技術 NPOT® (Nematic protein organisation technique) is a label-free cutting-edge technology for the isolation of native drug interactome directly from human samples. Interactome analysis enables ON and OFF target identification, MoA elcucidation and success predictive biomarkers.
PIMS® (Physiological Intermolecular Modulation Spectroscopy) is a labelè-free technology for patient stratification in responders and non-responders and target engagement analysis.

製品・技術の特徴

The current technologies available on the market to identify the target of compounds, and thus its mechanism of action, are all based on labeled approach, such as the chemoproteomic. Labeled techniques request linking the compound of interest to a chemical arm which is itself bound to another structure (solid phase). These techniques still have interest since they are affordable but they have strong limitations as they introduce bias since the compound structure is modified by the chemical arm bound to the compound. Another drawback of these techniques remain the time necessary to perform the chemistry, which slows down the drug target identification.
New label-free approaches are coming to the market such as CETSA (cellular thermal shift assay), DARTS (drug affinity responsive target stability) and LiP (Limited Proteolysis), however these techniques are reaching their limitations too as they are mostly efficient on soluble proteins but fail to identify membrane

Technology transfer, preclinical drug development
技術移転, 前臨床段階薬物開発

会社名 IOCB Tech
国名 Czech Republic (CZ)
ウェブサイト https://www.iocbtech.cz/

設立 2009年1月
社員数 < 10 employees　　**社員数 グループ**
売上 (EUR) 1 to 10　　**売上 (EUR) グループ**

会社概要

IOCB Tech is a technology transfer office and subsidiary company of IOCB (the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences). The company matches results of basic research done at the IOCB with needs of commercial partners to ultimately bring new ideas in medicinal chemistry, material sciences, and other fields of chemistry to human use.

IOCB Techは技術移転機関であり、IOCB（チェコ科学アカデミー、有機化学・生化学研究所）の子会社です。IOCB Techは、IOCBで行われた基礎研究の結果を商業パートナーのニーズにマッチさせ、最終的に医薬品化学、材料科学、その他化学分野の技術をヒト用製品開発に応用できる新しいアイディアを生み出します。

製品・技術

The IOCB Tech is the leading technology transfer office in the Czech Republic. Our mother organisation, the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB), is internationally recognized for its outstanding science in the field of chemistry. One of the Institute´s greatest strengths is its expertise in medicinal chemistry, gained through a long history of successful collaboration with pharma industry. A prominent example of such collaboration is IOCB´s contribution to the development of anti-HIV blockbuster drugs (e.g. Viread, Truvada – with Gilead Sciences). The IOCB continues in its quest for the development of novel drugs in therapeutic areas with high unmet medical needs. Our current endeavors include projects in neuropathic pain, T-cell leukemias and lymphomas, treatment-resistant infections, IBD, epilepsy, breast cancer, and endometriosis.

製品・技術の特徴

All projects in our portfolio focus on the development of novel drugs to tackle unmet medical needs in their respective therapeutic areas. To name a few examples, one of our projects targets T-cells leukemia and lymphomas, conditions that have been long underserved because of their relative rarity. In our CNS projects (epilepsy and neuropathic pain), we have developed compounds with a unique mechanism of action (distinct from currently marketed agents) and with preclinical efficacy comparable or superior to clinically used active comparators. Our anti-infective compounds are highly effective against a wide spectrum of bacterial pathogens, but unlike most marketed treatments, they have a low potential to induce resistance.

Design, development and manufacturing Medical devices and IVD tests
医療機器およびIVD(体外診断)検査の設計、開発、製造

会社名 Labmaster Oy
国名 Finland (FI)
ウェブサイト http://labmaster.fi

設立 1985年1月
社員数 10 - 49 employees　　**社員数 グループ** < 49 employees
売上 (EUR) < 1 million　　**売上 (EUR) グループ** 1 to 10

会社概要

Labmaster Ltd, based in Turku, Finland, is a privately owned company focusing on delivering innovative diagnostics tools for applications in routine clinical diagnostics and research. Labmaster develops and commercializes the next generation of versatile miniaturized detection tools based on its proprietary cathodic electrochemiluminescence-technology (LM-CECL).

Labmaster社は、フィンランドのトゥルクを拠点とした民間企業であり、日常臨床診断および研究向けの革新的な診断ツールを提供しています。Labmasterは、独自のカソード電気化学発光技術(LM-CECL)を基盤とした次世代型の多目的小型検出ツールを開発、製品化しています。

製品・技術

Labmaster LUCIA™ is a point-of-care (POC) platform based on patented CECL technology. Labmaster develops and commercializes the next generation of versatile miniaturized detection tools based on its proprietary cathodic electrochemiluminescence-technology (CECL).

製品・技術の特徴

Labmaster LUCIA™ is a point-of-care (POC) platform based on CECL technology.

≫ Easy to use and competitive pricing
≫ Highly sensitive assays
≫ Broad linear range

Aptamer-based biosensor design; custom Aptamer selection for therapeutics, diagnostics & analytics.
アプタマーを用いたバイオセンサーの設計：治療・診断・解析用カスタムアプタマーのオーダーメイド選択

会社名 Novaptech
国名 France (FR)
ウェブサイト novaptech.com

設立 2016年1月
社員数 < 10 employees
社員数 グループ < 49 employees
売上 (EUR) < 1 million
売上 (EUR) グループ < 1 million

会社概要

THINK APTAMERS! ALTERNATIVE TO ANTIBODIES
Novaptech engineers aptamer-based products. Aptamers are nucleic acid antibodies that bind to any target (small molecule, protein, virus, cell,…). Aptamers are nice tools for applications in pharma, environment and food safety. Novaptech offers R&D service and partnership based on its innovative technology for the development of biosensors and rapid tests.

－抗体の代替としてアプタマーをご検討ください－
Novaptechは、アプタマーを用いた製品を設計しています。アプタマーは、いかなるターゲット（小分子、タンパク質、ウイルス、細胞など）にも結合することができる核酸抗体です。アプタマーは、医薬品、環境、食品の安全に応用できる優れたツールです。Novaptechは、バイオセンサーと迅速検査の開発における独自の革新的技術を基盤とした研究開発サービスとパートナーシップを提供します。

製品・技術

Novaptech provides tools for rapid tests and point-of-care analysis. Novaptech also provides companies and academic laboratories worldwide with custom aptamers, either first generation aptamers selected through the standard “SELEX” procedure, or second generation aptamers – “APTASWITCHES” – for small molecules, identified through its innovative technology “SELKiss”. This process allows 1) the selection of aptamers against free target species in solution, 2) the direct functional identification of sensing ligands and 3) the downstream development of multiplexed devices. The aptamers obtained with “SELKiss” retain the advantages of these so-called “chemical antibodies” (strong affinity for their cognate ligand and high specificity of recognition). In addition, APTASWITCHES display signalling properties, circumventing the limits of the “SELEX” technology for conversion into sensing biomolecules and making them exquisite agents for the quantitative detection of molecules of interest – biomarkers, metabolites, drugs, pollutants – in real time and through diverse

製品・技術の特徴

Innovative: Novaptech technology makes use of a new process for the selection of aptamers. Termed SELKiss, this technology generates second generation aptamers named aptaswitches. Novaptech SELKiss and aptaswitches provide competitive advantage and key properties over standard procedure and products: no need of synthesis of a target analogue for its immobilization on solid support as SELKiss works with free target in solution. Aptaswitches that undergo a conformational change upon binding to the target are signaling entities avoiding post-selection engineering prior to insertion in biosensors. This results in shortened procedures and reduced costs.

Competitive advantages:
A) Aptamers (SELEX) over antibodies: The in vitro process for aptamer selection and their fast and controlled production ensure unrivalled benefits: no

Op2Lysis is dedicated to develop the best-in-class medical treatment for hemorrhagic stroke patients
Op2Lysisは出血性脳卒中患者に対する最高級の治療法開発に尽力いたします。

会社名 OpLysis SAS
国名 France (FR)
ウェブサイト www.op2lysis.com

設立 2016年1月
社員数 < 10 employees
社員数 グループ < 49 employees
売上 (EUR)
売上 (EUR) グループ

会社概要

Development of the best-in-class medical treatment to liquefy and remove safely the intracerebral hematoma consecutive to hemorrhagic stroke, the most severe form of stroke, which represents 30% of all strokes in the world and in Japan, and induces about 50% of the stroke burden costs. This is an unmet medical need and a very severe condition: 50% of death and 50% of severe disability in surviving patients.

Op2Lysisは、脳内血腫を液化し安全に除去するベストインクラス - 最高級の治療法を開発しています。脳内血腫は、脳卒中の中で最も重篤である出血性脳卒中の原因となることがあります。出血性脳卒中は、世界および日本において、全脳卒中の30%を占め、脳卒中による医療コストの50%を占めるといわれています。出血性脳卒中は、満たされない医療ニーズ (アンメットメディカルニーズ) のひとつであり、患者の50%が死亡し、残りの50%も重度の障害をもつにいたる重篤な疾患です。

製品・技術

We develop the first medical treatment for patients with a hemorrhagic stroke, the most detrimental form of stroke for which no clinically effective treatment is yet available.
Our product, O2L-001, has been invented and further improved with a formulation to provide a unique option dedicated to intra-cerebral administration and blood clot liquefaction .
We have now reached a unique selling proposition with best efficacy and safety profile :
1. improved efficacy to reduce blood hematoma volume
2. reduced risk of re-bleeding
3. reduced risk of neurotoxicity
Therefore, we anticipate a strong clinical benefit after intra-cerebral administration through a minimally invasive surgical procedure to liquefy and evacuate the hematoma consecutive to this form of stroke.

製品・技術の特徴

The value proposition is to address a pressing unmet medical need with potential for cost reduction for hospitals (e.g., decrease in duration of hospitalization) and payers (decrease in disability). The countries which are primarily targeted for the development and commercialization of our product are the USA, the European Union and Japan, which represent together a 1 billion Euros market potential. The high incidence of the hemorrhagic stroke population in Japan and the potential for early registration are additional highly attractive features.

Computational predictions of ADME/PK of drug candidates and other chemicals
医薬品候補化合物等のADME/PKを計算予測

会社名 PROSILICO
国名 Sweden (SE)
ウェブサイト http://prosilico.com/

設立 2014年1月
社員数 < 10 employees　　**社員数 グループ** < 49 employees
売上 (EUR) < 1 million　　**売上 (EUR) グループ** < 1 million

会社概要

PROSILICO focuses on the research and development of innovative technologies to provide high quality predictions of human clinical ADME/PK (Absorption, Distribution, Metabolism, Excretion, PharmacoKinetics) estimates of drug candidates and other chemicals directly from chemical structure. We are currently (and apparently) the world leading company within this field when it comes to quality and innovativity.

PROSILICOは、ヒト臨床ADME／PK（吸収、分布、代謝、排泄、薬物動態）を高精度で予測し、化学構造から薬剤候補を直接推定する革新的技術の開発に焦点を当てています。PROSILICOは品質ならび革新性において、本分野の世界トップ企業といわれています。

製品・技術

PROSILICO's major services/products/technologies within the human clinical ADME/PK-prediction field are 1) an extensive prediction platform and, 2) web-based software with instant predictions and optimization of molecules.

These are based on unique technology (AI, machine learning, conformal predictions), database and algorithms. Certainty, validation and quality assurance are important to us. To assure that we have made full internal cross-validations, benchmarking studies and let big international pharmaceutical companies validate our methods externally. We also apply conformal prediction methodology that gives guaranteed levels of confidence in predictions, which is something that has been missing within the field. In these tests our methods outperformed corresponding lab methods in accuracy and range, which is also a major achievement. This enables cost and time reductions, reduced drug synthesis and use of animals, frontloading of decision-making, improved productivity, enhanced

製品・技術の特徴

Through unique technology (AI, machine learning, conformal predictions), database and algorithms, a highly experienced team with 3 professors in ADME/PK, bioinformatics and chemistry and a PhD in computational chemistry (in total more than 100 years in drug discovery and develeopment), and extensive validations and benchmarking studies, we have been able to outperform both labs and other in-silico-developing institutions. In-silico methods in this field have until now (with the launch of our systems) been inferior to lab methods, and normally, they have not been successful in true forward-looking predictions and avoided to demonstrate validation results. Apparently, we are the leading company within this field.
What normally takes weeks to months and costs >5000-50000 USD at labs and fails in more than 2 cases out of 3 (according to literature and our own investingations) can now be done with higher quality and certainty within a

3D cell culture, drug research, hydrogel for 3D cell cultures, cancer research, R&D
三次元細胞培養、医薬品研究、三次元培養用ハイドロゲル、がん研究、研究開発

会社名 Real Research Sp z o.o.
国名 Poland (PL)
ウェブサイト www.realresearch.life

設立 2017年1月
社員数 < 10 employees **社員数 グループ**
売上 (EUR) < 1 million **売上 (EUR) グループ**

会社概要

Real Research specializes in innovative solutions in biotechnology. Our main mission is to propagate 3D cell cultures that imitate physiological conditions for drug tests as well as for primary research. There is lot of scientific data showing that research done using 3D cell cultures result in greater predictability of the results comparing to the later clinical trials. Currently too many drugs are being rejected because of inapropriet preclinical research. We deeply believe that LifeGel can revolutionize how the LifeScience will be done in the future and this way increase the quality of the future drugs.

Real Reserchの主なミッションは、薬剤試験や初期研究に用いる、生理学的条件を模倣した三次元培養を普及させることです。
三次元培養を用いた研究ではより優れた結果予測可能性が得られ、後に行う治験の失敗する確率を低減することができます。LifeGelは未来のライフサイエンスに革命を起こし、将来の医薬品の品質向上を可能にします。

製品・技術

Real Research is a company operating in the LifeScience sector. Our first product is a protein hydrogel – LifeGel. It is the first commercially available hydrogel with a protein structure that is free from growth factors and highly reproducible and scalable in the production process. These features make it an ideal tool for 3D cell cultures. With LifeGel , cells live in an organism–like environment, which has a groundbreaking effect on the quality of the final results. The use of LifeGel for cell culture will allow the development of cells similar to those observed in the organism, which in turn gives more reliable results e. g. testing drug doses, therapy regimen, toxicity etc. We are offering LifeGel as a product for sale but we also perform services based on LifeGel technology. Our services include contracted research like e.g. angiogenesis assay but also developmental research where for clients need we can develop a research model for various types of diseases.

製品・技術の特徴

Our main product is a protein hydrogel – LifeGel, widely used in three–dimensional cell cultures. The innovative aspect of LifeGel is based on its production technology. It is the first protein hydrogel on the market with a protein structure that is 100% free of growth factors, while maintaining high repeatability between production lots. These features provide a high economic profit that manifests itself in greater research efficiency, as well as maintaining high repeatability of conducted experiments. The main benefit of our product is to obtain culturing conditions that are convertible to physiological/in vivo conditions, which is guaranteed by the purity of the product and its protein structure. LifeGel is highly repetitive and has a defined structure (similar to synthetic scaffolds with a chemically defined structure), and also has a protein structure resembling the environment in which cells live (similar to gels made from tumor tissues). LifeGel combines all the advantages of competitive

Drug Discovery, Computational and Medicinal Chemistry
創薬、計算化学、医科学

会社名 Taros Chemicals GmbH & Co. KG
国名 Germany (DE)
ウェブサイト https://www.taros.de

設立 1999年1月
社員数 10 – 49 employees　　**社員数 グループ** < 49 employees
売上 (EUR) 1 to 10　　**売上 (EUR) グループ** 1 to 10

会社概要

Taros is a privately owned discovery chemistry company which creates drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas. Taros' core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.

Tarosは、新薬候補物質を創出する民間の創薬化学企業です。Tarosはあらゆる主要治療領域において、数多くの生体分子ターゲットに関する優れた科学的実績を残しています。Tarosの核となる幅広い専門技術は、カスタム合成やプロセス開発、近代医学や計算科学のほか、化合物ライブラリの設計や作製にまでおよびます。

製品・技術

Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros' drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros' core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.

製品・技術の特徴

We are involved in some very unique drug discovery projects tackling unmet medical needs that could be of interest to Japanese pharmaceutical companies to consider. Moreso, we have designed and produced a series of HTS and Fragment based compound libraries that are very different in nature than what currently is available on the market with commercial vendors. The uniqueness of our designs has been related to in numerous scientific publications . Our compound libraries have a high degree of 3D structure and are unprecedented in the small molecules libraries of the pharmaceutical industry. In addition, we are Our capabilities could play a key role in supporting Japanese Pharma companies in finding innovative new drug during the the eary drug discovery phases. In order to identify and discuss scientific approaches, personal interactions between subject matter experts are of a very high impact. We believe the BIOJapan to be an exellent platform offering such opportunities of face to face